Division of Diagnostic Services, Department of Laboratory Medicine, University Hospital of North-Norway, 9038, Tromsø, Norway.
Department of Medical Biology, Faculty of Health Sciences, UiT-The Arctic University of Norway, 9037, Tromsø, Norway.
Acta Diabetol. 2024 Jul;61(7):847-857. doi: 10.1007/s00592-024-02266-5. Epub 2024 Mar 18.
We aimed to investigate changes in pre-diagnostic concentrations of classic and 11-oxygenated androgens in type 2 diabetes (T2DM) cases and healthy controls, associations between androgen concentrations and T2DM, and the potential for androgens to improve the prediction of T2DM when considered in combination with established risk factors.
Androgen concentrations were analysed in serum samples from 116 T2DM cases and 138 controls at 3, pre-diagnostic time-points: 1986/87 (T1), 1994/95 (T2), and 2001 (T3). Generalised estimating equations were used to longitudinally examine androgen concentrations, and logistic regression models were used to estimate the odds ratios (OR) of T2DM at each time-point. Logistic regression models were also used to calculate area under the receiver operating characteristics curve (AROC) from models including established risk factors alone (ERF model) and established risk factors plus each androgen, respectively, which were compared to identify improvements in predictive ability.
For women, no significant associations were observed between any of the investigated androgens and T2DM after adjusting for confounders. For men, after adjusting for confounders, concentrations of all investigated 11-oxygenated androgens were higher in cases than controls at one or several time-points. We observed associations between T2DM and concentrations of 11-ketoandrostenedione (OR: 1.59) and 11-ketotestosterone (OR: 1.62) at T1; and 11-hydroxyandrostenedione (OR: 2.00), 11-hydroxytestosterone (OR: 1.76), 11-ketoandrostenedione (OR: 1.84), 11-ketotestosterone (OR: 1.78) and testosterone (OR: 0.45) at T3 in men. The addition of these androgens (including 11-hydroxytestosterone at T2) to the ERF model resulted in an improved ability to predict T2DM in men (AROC: 0.79-0.82). We did not observe significant differences in changes in androgen concentrations over time between cases and controls in either sex.
Our results demonstrate that testosterone and 11-oxygenated androgens are associated with T2DM in men before diagnosis and may be potential biomarkers in T2DM risk assessment.
我们旨在研究 2 型糖尿病(T2DM)病例和健康对照者在诊断前经典和 11-氧代雄激素浓度的变化,以及雄激素浓度与 T2DM 的相关性,以及当考虑与既定危险因素联合使用时,雄激素对改善 T2DM 预测的潜力。
在 3 个时间点(1986/87 年(T1)、1994/95 年(T2)和 2001 年(T3))分析了 116 例 T2DM 病例和 138 例对照者的血清样本中的雄激素浓度。使用广义估计方程对雄激素浓度进行纵向检查,并使用逻辑回归模型估计每个时间点 T2DM 的比值比(OR)。逻辑回归模型还用于计算仅包括既定危险因素(ERF 模型)和每个雄激素的模型的接收器操作特征曲线下面积(AROC),并比较以确定预测能力的提高。
对于女性,在调整混杂因素后,没有观察到任何研究的雄激素与 T2DM 之间存在显著关联。对于男性,在调整混杂因素后,在一个或多个时间点,所有研究的 11-氧代雄激素的浓度在病例中均高于对照。我们观察到 T2DM 与 11-酮雄烯二酮(OR:1.59)和 11-酮睾丸酮(OR:1.62)在 T1 时的浓度之间存在关联;以及 11-羟基雄烯二酮(OR:2.00)、11-羟睾丸酮(OR:1.76)、11-酮雄烯二酮(OR:1.84)、11-酮睾丸酮(OR:1.78)和睾酮(OR:0.45)在 T3 时在男性中。将这些雄激素(包括 T2 时的 11-羟睾丸酮)添加到 ERF 模型中,导致男性 T2DM 预测能力的提高(AROC:0.79-0.82)。我们没有观察到男性和女性病例与对照者之间雄激素浓度随时间的变化有显著差异。
我们的结果表明,在诊断前,睾酮和 11-氧代雄激素与男性 T2DM 相关,可能是 T2DM 风险评估中的潜在生物标志物。